RPG Life Sciences Limited reported a 15.8% year-on-year increase in consolidated revenue from operations to ₹195.7 crore for the quarter ended June 30, 2026 (Q1FY27), driven by robust domestic formulation sales and a significant recovery in its API segment. Consolidated profit after tax (PAT) rose 17.0% to ₹30.8 crore from ₹26.3 crore in the prior year period, while EBITDA expanded 17.9% to ₹48.0 crore with margins improving to 24.5% from 24.1%. The Board of Directors approved the unaudited financial results on July 28, 2026, following review by the Audit Committee and limited review by statutory auditors S R B C & Co LLP pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were subsequently published in Business Standard and Mumbai Lakshadeep on July 29, 2026.

The company’s performance was anchored by its Domestic Formulations (DF) business, which contributed 68.3% of total sales and grew 14.8% to ₹132.5 crore, outperforming the broader Indian Pharma Market growth of 11.6%. This growth was supported by key therapy focus, new product introductions in specialty and chronic segments, and improved field-force effectiveness, with productivity exceeding ₹6.5 lakh per member. International Formulations registered 7.7% growth to ₹35.0 crore, contributing 18.0% to total sales. The API business delivered a strong 35.6% growth to ₹26.6 crore as units returned to operations following a fire incident in one of the manufacturing blocks during the prior year.

Financial Performance Highlights

Consolidated revenue from operations stood at ₹195.7 crore for the quarter, up from ₹168.9 crore in Q1FY26. Profit before tax (PBT) increased 17.0% to ₹41.5 crore from ₹35.4 crore, with PBT margin expanding slightly to 21.2% from 21.0%. Finance costs remained low, supporting bottom-line expansion. No exceptional items were recorded in Q1FY27, unlike the previous fiscal year which saw impacts from insurance claims and new labour codes.

On a standalone basis, revenue came in at ₹196 crore versus ₹170 crore in the corresponding quarter of the previous year. Standalone EBITDA stood at ₹43.6 crore compared to ₹35.5 crore, with standalone EBITDA margin improving to 22.27% from 21.0%. Standalone net profit was ₹30.6 crore versus ₹26.3 crore in the prior year period. Earnings per share (basic and diluted) rose to ₹18.49 from ₹15.90 in the corresponding quarter of the previous year.

Strategic Roadmap and Market Position

RPG Life Sciences outlined a seven-pillar strategic roadmap to drive future growth, focusing on portfolio development, mega-brand building, and digital transformation. The company aims to grow its immunosuppressant portfolio to over ₹200 crore and scale core brands like Naprosyn towards becoming a ₹100 crore+ brand. Key brands such as Naprosyn grew at 16%, alongside double-digit growth in nephrology and rheumatology baskets. The company also entered the coveted list of "Top 50 Pharma Companies" in India as per the Indian Pharma Market report for June 2026, advancing its ranking from 62 in March 2025 to 50 in June 2026.

ICRA reaffirmed the long-term rating at A+ with a stable outlook, citing robust capital structure, healthy cash flows, and no debt-funded capital expenditure. The credit agency highlighted steady top-line growth and improving operating margins as key factors supporting the rating affirmation. RPG Life Sciences also received three industry awards in Q1FY27, including "Top Nephrology Company-2026" by India Pharma Outlook, recognizing its strong patient care through a robust portfolio in the kidney care space.

What the Numbers Show

The expansion in EBITDA margin despite rising operational costs indicates effective cost management and pricing power in core therapeutic areas. The divergence between domestic formulation growth (14.8%) and market growth (11.6%) highlights RPG Life Sciences' competitive advantage in its home market. The significant recovery in the API segment suggests successful operational turnaround efforts, contributing to the overall robustness of the earnings profile. With ₹185+ crore capex infused since FY22 helping build modern plants with EU, TGA, and PMDA approvals, the company is well-positioned to capitalize on global opportunities while strengthening its domestic presence.

RPG Life Sciences reported a 16% year-on-year increase in standalone net profit to ₹305.7 lakh for the quarter ended June 30, 2026, driven by an 18.5% surge in revenue from operations. Consolidated net profit rose 17% to ₹307.6 lakh, reflecting consistent operational performance across its pharmaceutical segment. The results were approved by the Board of Directors at a meeting held on July 28, 2026, and reviewed by statutory auditors S R B C & Co LLP under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Revenue from operations grew to ₹195.69 crore in Q1FY26, up from ₹168.92 crore in the corresponding quarter of FY25. Total income stood at ₹199.85 crore on a standalone basis and ₹200.39 crore on a consolidated basis. The company operates in a single reportable business segment: Pharmaceuticals. Earnings per share (basic) increased to ₹18.49 from ₹15.90 in Q1FY25, while diluted EPS remained identical to basic figures.

Financial Performance

Total expenses rose to ₹158.64 crore (standalone) and ₹158.93 crore (consolidated), primarily due to higher purchases of stock-in-trade and employee benefits expense. Finance costs remained minimal at ₹6.3 lakh. Income tax expenses were recorded at ₹10.64 crore (standalone) and ₹10.70 crore (consolidated).

Strategic Developments

The Board approved the transfer of its API division to wholly owned subsidiary RPG Active Pharma Limited, incorporated on December 24, 2025. This transaction, approved on December 15, 2025, is subject to requisite regulatory consents and customary conditions precedent. The company continues to monitor the impact of New Labour Codes notified effective November 22, 2025, which resulted in exceptional expenses of ₹116.9 lakh during FY26 due to changes in wage definitions.

What the Numbers Show

The divergence between revenue growth (18.5%) and net profit growth (16%) suggests modest margin compression, likely influenced by higher input costs and labor-related expenses. However, the absence of exceptional items in Q1FY26—unlike FY26 which included insurance claim settlements and impairment charges—indicates that core operational profitability has strengthened independently of one-off gains. The stable finance costs and controlled tax outlays further support sustainable earnings quality.